Accessibility Menu
Panacea Life Sciences logo

Panacea Life Sciences(OTC) PLSH

Market Cap$6.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-97%
5 Year-96%
1 Year+96%
1 Month+8%
$0.10
+1.22%
+0.00Today
Panacea Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.102026-08-31
Panacea Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.32%USD 0.092026-08-24
1 month+8.24%USD 0.092026-07-30
3 month+185.71%USD 0.042026-06-02
Year to date+100%USD 0.052025-12-31
1 year+96.08%USD 0.052025-08-29
3 year-50%USD 0.202023-09-01
5 year-95.52%USD 2.232021-09-01
Since inception-97.37%USD 3.812021-07-01

Panacea Life Sciences Financials at a Glance

Market Cap

$6.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$263.95K

Net Income (TTM)

-$5.67M

EPS (TTM)

-$0.10

P/E Ratio

-0.98

Dividend

$0.00

Beta (Volatility)

-5.56 (Low)

Price

$0.10

Volume

2,500

Open

$0.10

Previous Close

$0.10

Daily Range

$0.10 - $0.10

52-Week Range

$0.02 - $0.20

Estimated Earnings Date

Aug 13, 2026

PLSH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Panacea Life Sciences

Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products. The company focuses on developing natural, pharmaceutical-grade alternatives for both human and pet consumption.

Products and Services
  • Offers a diverse range of cannabinoid products including softgels, gummies, and tinctures
  • Involved in personal protective equipment (PPE) market, distributing hand sanitizers and masks
  • Provides white-label and contract manufacturing services to other cannabinoid companies
Growth Outlook
  • Expanding product lines to meet increasing consumer demand for natural alternatives
  • Strategic partnerships in the cannabinoid sector to enhance market reach
  • Focus on research and development to innovate new product offerings
Financial Highlights
  • Recent quarterly revenue of 45,631, showing potential for growth
  • Trailing twelve months (TTM) revenue of 1,000,000, indicating a solid market presence
  • Current ratio of 2.30, suggesting strong short-term financial health
Panacea Life Sciences Holdings, Inc. is positioned in the growing cannabinoid and nutraceutical market, with a focus on delivering high-quality products. The company’s diverse offerings and strategic initiatives aim to capitalize on the increasing consumer interest in natural health solutions. Recent financial data indicates a revenue trajectory that may attract potential investors looking for opportunities in the healthcare sector. The company's commitment to innovation and quality positions it well for future growth in a competitive landscape.
AI Generated • Sep 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1

CEO

Leslie Buttorff

Website

www.panacealife.com

Headquarters

Greenwood Village, CO 80121, US

PLSH Financials

Key Financial Metrics (TTM)

Gross Margin

-612.89%

Operating Margin

-289.21%

Net Income Margin

-2147.67%

Return on Equity

-145.76%

Return on Capital

-31.33%

Return on Assets

-426.41%

Earnings Yield

-1.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

67.99M

Volume

2.50K

Avg. Volume

15.42K

Financials (TTM)

Gross Profit

-$1.62M

Operating Income

-$763.35K

EBITDA

-$2.66M

Operating Cash Flow

$459.02K

Capital Expenditure

-$6.00

Free Cash Flow

$459.01K

Cash & ST Invst.

$40.83K

Total Debt

$186.69K

Panacea Life Sciences Performance Analysis

Panacea Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,626,978-21.0%
20232023-12-31USD 2,384,95646.6%
20242024-12-31USD 3,179,58233.3%
20252025-12-31USD 910,518-71.4%
Panacea Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-76.9%
Q42025-12-31-0.1%
Q12026-03-31138.9%
Q22026-06-30-61.6%
Panacea Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.62129.2%
20232023-12-31USD -0.48-21.7%
20242024-12-31USD -0.23-52.1%
20252025-12-31USD -0.01-97.0%
Panacea Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-114.5%
Q42025-12-31-481.8%
Q12026-03-31-134.0%
Q22026-06-3079.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$45.63K

-78.8%

Gross Profit

$45.17K

-75.4%

Gross Margin

98.98%

N/A

Market Cap

$6.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.27M

N/A

Employees

3

N/A

Net Income

-$721.71K

-174.1%

EBITDA

-$70.09K

-104.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$40.83K

-83.2%

Total Debt

$186.69K

-98.4%

Accounts Receivable

$0.00

N/A

Inventory

$488.20K

-84.7%

Long Term Debt

$0.00

N/A

Short Term Debt

$186.69K

-98.4%

Return on Assets

-4.26%

N/A

Return on Invested Capital

-69.45%

N/A

Free Cash Flow

-$27.27K

+94.5%

Operating Cash Flow

-$27.27K

+94.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNNACann American Corp.
$0.01+0.00%
EXMTAnything Technologies Media, Inc.
$0.00+33.33%
CBDYTarget Group Inc.
$0.00+0.00%
MJARFMJardin Group, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About PLSH

What is the current price of Panacea Life Sciences?

Panacea Life Sciences is trading at $0.10 per share.

What is the 52-week range for Panacea Life Sciences?

Over the past 52 weeks, Panacea Life Sciences has traded between $0.02 and $0.20.

How much debt does Panacea Life Sciences have?

As of the most recent reporting period, Panacea Life Sciences reported total debt of $186.69K.

How much cash does Panacea Life Sciences have on hand?

Panacea Life Sciences reported $40.83K in cash and cash equivalents in its most recent financial results.

What is Panacea Life Sciences’s dividend yield?

Panacea Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services